180 related articles for article (PubMed ID: 7584088)
1. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.
Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL
Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088
[TBL] [Abstract][Full Text] [Related]
2. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
3. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
Ding Z; Georgiev P; Thöny B
Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
[TBL] [Abstract][Full Text] [Related]
4. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
5. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy.
Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627
[TBL] [Abstract][Full Text] [Related]
6. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K
Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.
Jung SC; Park JW; Oh HJ; Choi JO; Seo KI; Park ES; Park HY
J Korean Med Sci; 2008 Oct; 23(5):877-83. PubMed ID: 18955797
[TBL] [Abstract][Full Text] [Related]
8. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin.
Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG
Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Acta Paediatr Suppl; 1994 Dec; 407():124-9. PubMed ID: 7766948
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Eur J Pediatr; 1996 Jul; 155 Suppl 1():S16-9. PubMed ID: 8828602
[TBL] [Abstract][Full Text] [Related]
11. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector.
Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A
J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099
[TBL] [Abstract][Full Text] [Related]
12. Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy.
Yagi H; Sanechika S; Ichinose H; Sumi-Ichinose C; Mizukami H; Urabe M; Ozawa K; Kume A
Neuroreport; 2012 Jan; 23(1):30-4. PubMed ID: 22107842
[TBL] [Abstract][Full Text] [Related]
13. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
14. The structural basis of phenylketonuria.
Erlandsen H; Stevens RC
Mol Genet Metab; 1999 Oct; 68(2):103-25. PubMed ID: 10527663
[TBL] [Abstract][Full Text] [Related]
15. A heteroallelic mutant mouse model: A new orthologue for human hyperphenylalaninemia.
Sarkissian CN; Boulais DM; McDonald JD; Scriver CR
Mol Genet Metab; 2000 Mar; 69(3):188-94. PubMed ID: 10767173
[TBL] [Abstract][Full Text] [Related]
16. Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes.
Christensen R; Kolvraa S; Blaese RM; Jensen TG
Gene Ther; 2000 Dec; 7(23):1971-8. PubMed ID: 11175307
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the mouse phenylalanine hydroxylase mutation Pah(enu3).
Haefele MJ; White G; McDonald JD
Mol Genet Metab; 2001 Jan; 72(1):27-30. PubMed ID: 11161825
[TBL] [Abstract][Full Text] [Related]
18. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector.
Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F
Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550
[TBL] [Abstract][Full Text] [Related]
19. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.
Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO
Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130
[TBL] [Abstract][Full Text] [Related]
20. The PAH gene, phenylketonuria, and a paradigm shift.
Scriver CR
Hum Mutat; 2007 Sep; 28(9):831-45. PubMed ID: 17443661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
